GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
Baker Bros. Advisors and affiliates reported a 5.3% stake in GRAIL, Inc. common stock. They beneficially own 2,085,333 shares, held through funds 667, L.P. and Baker Brothers Life Sciences, L.P., which together control this position.
The ownership calculation is based on 38,982,223 GRAIL shares outstanding as of November 10, 2025. Part of the position includes pre-funded warrants exercisable at $0.001 per share, but these can only be exercised within limits that cap aggregate beneficial ownership at 4.99%, adjustable up to 19.99% with advance notice.
PRIMECAP Management Co. filed an amended Schedule 13G reporting its beneficial ownership in GRAIL, Inc. as of the event date. The firm reports holding 1,838,684 shares, representing 4.72% of GRAIL’s outstanding common stock, with sole voting power over 1,836,818 shares.
PRIMECAP has sole dispositive power over all 1,838,684 shares and no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of GRAIL.
GRAIL, Inc. received an updated ownership filing from a group of Farallon-affiliated investment funds and managers. They report beneficial ownership of 2,342,684 shares of GRAIL common stock, including shares underlying 571,021 pre-funded common stock purchase warrants, representing 5.9% of the class as of 12/31/2025.
The warrants carry a 9.99% beneficial ownership cap, but currently do not limit exercise, so all underlying shares are counted as beneficially owned. The amendment also records governance changes: Avner A. Husen is added as a Farallon managing member effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel, and William Seybold ceased such roles effective December 31, 2025 and are no longer deemed beneficial owners.
GRAIL, Inc. director William J. Chase received an equity grant for his board service. On January 15, 2026, he was granted 213 deferred stock units of GRAIL common stock at a price of $97.44 per share, in lieu of $20,794.52 of cash fees otherwise payable for his role as a director.
These awards vest immediately on the grant date, meaning the units are fully earned right away. Following this transaction, Chase beneficially owned 36,803 shares of GRAIL common stock in direct form.
GRAIL, Inc. director Gregory L. Summe received equity compensation instead of cash fees. On January 15, 2026, he was granted 329 deferred stock units of GRAIL common stock, recorded at a price of $97.44 per share, in lieu of $32,136.98 in cash director fees. These awards vest immediately on the grant date and increase his directly held beneficial position to 39,123 shares of common stock. This filing reflects routine director compensation paid in stock units rather than cash.
GRAIL director Steven Mizell received 206 deferred stock units of common stock on January 15, 2026 as director compensation. These units were granted under the company’s deferred stock program and 2024 Incentive Award Plan in lieu of $20,164.38 of cash fees for his board service, using a price of $97.44 per share, which matched the closing market price on the grant date. The awards vest immediately upon grant, meaning they are fully earned right away. Following this grant, Mizell directly beneficially owns 36,675 shares of GRAIL common stock.
GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The company states that the slide presentation to be used at the conference is being furnished as Exhibit 99.1 to this current report. The company clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, meaning it is not subject to certain liabilities under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless specifically referenced. The report is signed on behalf of GRAIL by its Chief Financial Officer, Aaron Freidin.
GRAIL, Inc.'s Chief Financial Officer reported an insider sale of company stock. On 12/03/2025, the reporting person sold 25,000 shares of GRAIL common stock in an open market transaction coded "S" (sale). The weighted average sale price was $99.1527 per share, with individual trades executed between $99.00 and $99.76.
After this transaction, the reporting person beneficially owned 259,077 shares of GRAIL common stock, held directly. The footnote explains that the reported price is an average across multiple trades and that detailed trade-level pricing information within the stated range is available upon request.
GRAIL, Inc. (GRAL) reported an insider tax-related stock sale by its Chief Financial Officer. On 11/17/2025, the CFO disposed of 1,697 shares of common stock in an automatic sell-to-cover transaction at a weighted average price of $79.2 per share. These sales were executed by a broker to cover withholding taxes due upon the vesting and delivery of an equity award, rather than as a discretionary open-market sale.
After this transaction and a small correction of 10 shares to fix a prior reporting error, the reporting person beneficially owns 284,077 shares of GRAIL common stock, including 641 shares acquired through the company’s employee stock purchase plan on November 14, 2025.
GRAIL, Inc. reported two capital markets updates. The company filed a prospectus supplement for the resale of 3,925,767 shares of common stock previously issued to selling stockholders, consisting of 1,927,194 shares and 1,998,573 shares issuable upon exercise of pre-funded warrants. These securities were issued under a securities purchase agreement dated October 18, 2025 and are covered by GRAIL’s Form S-3 shelf.
GRAIL also entered an Equity Distribution Agreement with Morgan Stanley and TD Securities to establish an at-the-market program allowing sales of up to $300,000,000 of common stock from time to time. Sales may be made in transactions permitted by Rule 415, with a commission of up to 3.0% of gross proceeds payable to the sales agents. Related legal opinions and the agreement were filed as exhibits.